Search results for "DOT"

showing 10 items of 5147 documents

Atrial Fibrillation Is Associated with a Marker of Endothelial Function and Oxidative Stress in Patients with Acute Myocardial Infarction

2015

International audience; Background Atrial fibrillation (AF), whether silent or symptomatic, is a frequent and severe complication of acute myocardial infarction (AMI). Asymmetric dimethylarginine (ADMA), an endogenous eNOS inhibitor, is a risk factor for endothelial dysfunction. We addressed the relationship between ADMA plasma levels and AF occurrence in AMI.Methods 273 patients hospitalized for AMI were included. Continuous electrocardiographic monitoring (CEM) !48 hours was recorded and ADMA was measured by High Performance Liquid Chromatography on admission blood sample.Results The incidence of silent and symptomatic AF was 39(14%) and 29 (11%), respectively. AF patients were markedly o…

Aged 80 and overMalelcsh:RMyocardial Infarctionlcsh:MedicineMiddle AgedArginineRisk Assessment[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemElectrocardiographyOxidative StressLogistic Models[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRisk FactorsAtrial FibrillationMultivariate AnalysisHumansFemalelcsh:QEndotheliumlcsh:ScienceBiomarkersChromatography High Pressure LiquidResearch ArticleAged
researchProduct

miR-126-3p and miR-21-5p as Hallmarks of Bio-Positive Ageing; Correlation Analysis and Machine Learning Prediction in Young to Ultra-Centenarian Sici…

2022

Human ageing can be characterized by a profile of circulating microRNAs (miRNAs), which are potentially predictors of biological age. They can be used as a biomarker of risk for age-related inflammatory outcomes, and senescent endothelial cells (ECs) have emerged as a possible source of circulating miRNAs. In this paper, a panel of four circulating miRNAs including miR-146a-5p, miR-126-3p, miR-21-5p, and miR-181a-5p, involved in several pathways related to inflammation, and ECs senescence that seem to be characteristic of the healthy ageing phenotype. The circulating levels of these miRNAs were determined in 78 healthy subjects aged between 22 to 111 years. Contextually, extracellular miR-1…

Aged 80 and overSettore MED/04 - Patologia Generaleageing; inflamm-ageing; endothelial senescence; longevity; miRNAsagingEndothelial Cellsinflamm-ageingGeneral Medicineinflamm-agingMachine LearningMicroRNAslongevityageingendothelial senescenceCentenariansmiRNAsHumansCirculating MicroRNABiomarkersCells; Volume 11; Issue 9; Pages: 1505
researchProduct

Regulatory mechanisms of estrogen on vascular ageing

2019

Women can be considered hemodynamically younger than men of the same age, based on epidemiological studies establishing that the incidence of vascular diseases in women is relatively lower compared to that in aged-matched men. However, after menopause, these numbers increase to values that are close to those found in men. Vascular ageing is associated with structural and functional changes of the vascular wall, including endothelial dysfunction, arterial stiffening, and remodelling, as well as impaired angiogenesis, which become major risk factors in the development of cardiovascular disease.

AgingEndotheliumArticle Subjectbusiness.industrymedicine.drug_classlcsh:CytologyEstrogensCell BiologyGeneral MedicineBioinformaticsBiochemistryVascular ageingmedicine.anatomical_structureText miningEditorialEstrogenMedicineHumansFisiologia humanaFemaleEndothelium Vascularlcsh:QH573-671businessSistema cardiovascular
researchProduct

Developmental Changes and Daily Rhythm in Melatonin-Induced Inhibition of 3′,5′-Cyclic AMP Accumulation in the Rat Pituitary

1990

Melatonin's transduction mechanisms were investigated using in vitro cultured anterior hemipituitaries. Melatonin inhibited cAMP and 3',5'-cyclic GMP accumulation in neonatal rat anterior pituitary stimulated with LHRH. Maximal inhibitory effect was reached within 25 min and persisted for at least 20 min. Inhibition of cAMP accumulation is specific for melatonin because its analogs N-acetylserotonin and 5-methoxytryptamine are 1000 times less potent. Melatonin effect is age- and time-dependent. Marked inhibition was observed in 5-, 10-, and 14-day-old rats but not in 29-day-old ones. Melatonin was significantly more potent when applied at the end of the light period as compared with the fir…

Agingendocrine systemmedicine.medical_specialtyPituitary glandTime FactorsGonadotropin-releasing hormoneIn Vitro TechniquesBiologyGonadotropin-Releasing HormoneMelatoninEndocrinologyAnterior pituitaryInternal medicineCyclic AMPmedicineAnimalsCircadian rhythmCyclic GMPMelatoninDose-Response Relationship DrugRats Inbred StrainsCircadian RhythmRatsDose–response relationshipEndocrinologymedicine.anatomical_structurePituitary GlandSecond messenger systemhormones hormone substitutes and hormone antagonistsEndocrine glandmedicine.drugEndocrinology
researchProduct

Can the effects of gender, menopause and ageing on lipid levels be differentiated?

2016

The menopause, as well as ageing in both genders, can influence cardiovascular disease (CVD) risk1. An atherogenic lipoprotein profile, including small dense low density lipoprotein (sdLDL) particles, can be present even in normolipidaemic healthy young individuals (about 6%)2. If confirmed by larger studies, it will be necessary to consider different risk stratifications for those with atherogenic normolipidaemia and those with non-atherogenic hypercholesterolaemia. Furthermore, other changes associated with the menopause (increase in lipoprotein (a) [Lp(a)] levels, central obesity, endothelial dysfunction and systemic inflammation) may contribute to pro-atherogenic changes, while ethnicit…

Agingmedicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030204 cardiovascular system & hematologySystemic inflammation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumans030212 general & internal medicineEndothelial dysfunctionbusiness.industrymedicine.diseaseLipidsObesityMenopauseEndocrinologychemistryAgeingLow-density lipoproteinFemaleMenopausemedicine.symptombusinessLipoproteinClinical Endocrinology
researchProduct

Magnesium and type 2 diabetes.

2015

Type 2 diabetes is frequently associated with both extracellular and intracellular magnesium (Mg) deficits. A chronic latent Mg deficit or an overt clinical hypomagnesemia is common in patients with type 2 diabetes, especially in those with poorly controlled glycemic profiles. Insulin and glucose are important regulators of Mg metabolism. Intracellular Mg plays a key role in regulating insulin action, insulin-mediated-glucose-uptake and vascular tone. Reduced intracellular Mg concentrations result in a defective tyrosine-kinase activity, postreceptorial impairment in insulin action and worsening of insulin resistance in diabetic patients. A low Mg intake and an increased Mg urinary loss app…

Agingmedicine.medical_specialtySettore MED/09 - Medicina InternaDiabetes riskEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesHypomagnesemiaInsulin resistanceInternal medicineDiabetes mellitusInternal MedicinemedicineMagnesiumEndotheliumAging; Endothelium; Hypertension; Inflammation; Insulin resistance; Magnesium; Metabolic syndrome; Type 2 diabetesGlycemicInflammationbusiness.industryInsulinInsulin resistanceType 2 diabetesMinireviewsmedicine.diseaseMetabolic syndromeEndocrinologyHypertensionMetabolic syndromebusinessWorld journal of diabetes
researchProduct

Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin.

1994

1. The effects of vasopressin and deamino-8-D-arginine vasopressin (DDAVP, desmopressin) were studied in artery rings (0.8-1 mm in external diameter) obtained from portions of human omentum during the course of abdominal operations (27 patients). 2. In arterial rings under resting tension, vasopressin produced concentration-dependent, endothelium-independent contractions with an EC50 of 0.59 +/- 0.12 nM. The V1 antagonist d(CH2)5Tyr(Me)AVP (1 microM) and the mixed V1-V2 antagonist desGly-d(CH2)5D-Tyr(Et)ValAVP (0.01 microM) displaced the control curve to vasopressin to the right in a parallel manner without differences in the maximal responses. In the presence of indomethacin (1 microM) the…

AgonistAdultMaleVasopressinmedicine.medical_specialtymedicine.drug_classVasopressinsMuscle RelaxationIndomethacinVasodilationIn Vitro TechniquesArginineNitric OxideMuscle Smooth VascularInternal medicineArginine vasopressin receptor 2medicineHumansDeamino Arginine VasopressinMesenteric arteriesVasopressin receptorPharmacologyChemistryAntagonistMiddle AgedReceptor antagonistMesenteric ArteriesArginine VasopressinEndocrinologymedicine.anatomical_structureNG-Nitroarginine Methyl EsterFemaleEndothelium Vascularhormones hormone substitutes and hormone antagonistsResearch ArticleMuscle Contraction
researchProduct

GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.

2009

The use of gonadotrophin-releasing hormone (GnRH) agonists for triggering ovulation remains controversial. The primary objective of this study was to evaluate the incidence of ovarian hyperstimulation syndrome (OHSS) following GnRH agonist versus recombinant human chorionic gonadotrophin (HCG) as methods for triggering ovulation. A second aim was to compare the clinical outcome and embryo quality according to the two procedures. The cycle characteristics of 100 oocyte donors undergoing ovarian stimulation and IVF outcomes of their 100 oocyte recipients were analysed. Donors were prospectively randomized into two groups on the last day of ovarian stimulation: Group I received a single bolus …

AgonistAdultendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectOvarian hyperstimulation syndromeFertilization in VitroChorionic GonadotropinAndrologyGonadotropin-Releasing HormoneOvarian Hyperstimulation SyndromeOvulation InductionPregnancymedicineHumansOvulationmedia_commonGynecologyPregnancyIn vitro fertilisationTriptorelin PamoateOocyte Donationbusiness.industryObstetrics and GynecologyOocytemedicine.diseaseTriptorelinRecombinant Proteinsmedicine.anatomical_structureTreatment OutcomeReproductive MedicineFemalebusinesshormones hormone substitutes and hormone antagonistsEmbryo qualityDevelopmental Biologymedicine.drugReproductive biomedicine online
researchProduct

Concomitant gonadotropin-releasing hormone agonist and menotropin treatment for the synchronized induction of multiple follicles.

1988

In an effort to overcome possible interference by endogenous gonadotropin-ovarian hormone dynamics, desensitization of the pituitary gonadotropins by a gonadotropin-releasing hormone agonist (GnRHa) was achieved in 12 women with repeatedly failed attempts at multiple follicular stimulation. Eight women were scheduled for in vitro fertilization (IVF) and embryo transfer (ET), and 4 for gamete intrafallopian transfer (GIFT). Stimulation failure was characterized by premature luteinization, poor estradiol (E2) response, or inadequate follicular growth. The agonist was administered by nasal spray 500 to 600 micrograms/day beginning on days 21 to 23 of the menstrual cycle. A rapid desensitizatio…

AgonistAdultendocrine systemmedicine.medical_specialtyMenotropinsmedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentFertilization in VitroBiologyBuserelinReproductive TechniquesOvulation InductionInternal medicineGonadotropin-releasing hormone agonistFollicular phasemedicineHumansGamete intrafallopian transferMenstrual cyclemedia_commonIn vitro fertilisationObstetrics and GynecologyEmbryo TransferEmbryo transferEndocrinologyReproductive MedicineFemaleMenotropinhormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist…

2005

Background This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles. Methods Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol). Vaginal progesterone (200 mg/day) was administered in the luteal phase. Endometrial biopsies were performed 2 and 7 days after HCG administration. Additional biopsies were carried out in a subset of 12 subjects, 2 and 7 days following the LH peak of their previous natural cycle. Biopsies were evaluated histologi…

AgonistAdultendocrine systemmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentFertilization in VitroLuteal phaseBiologyLuteal PhaseEndometriumBuserelinChorionic GonadotropinGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneEndometriumOvulation InductionInternal medicinemedicineHumansUltrasonicsGanirelixOligonucleotide Array Sequence Analysismedicine.diagnostic_testOocyte DonationRehabilitationObstetrics and GynecologyBuserelinmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationReceptors EstrogenMicroscopy Electron ScanningOocytesRNAOvulation inductionFemaleFollicle Stimulating HormoneReceptors Progesteronehormones hormone substitutes and hormone antagonistsmedicine.drugEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct